// App-Quantinova.ai

DMT49 : Pregnancy Outcomes Following Exposure to Ofatumumab in Patients with MS: Results from the Prim Study

Researchers

Presenter

  • Riley Bove

Principal Investigators

  • Maria Pia Amato

  • Ruth Dobson

  • Kristen M Krysko

  • Sharon Stoll

  • Sandra Vukusic

  • Bassem Yamout

  • Ronald Zielman

  • Krishna Swetha Gummuluri

  • Valentine Jehl

  • Ulf Schulze Topphoff

  • Roseanne Sullivan

  • Kerstin Hellwig

Medical Centers

  • St. Josef-Hospital/Ruhr-University Bochum

  • Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon Université Claude Bernard Lyon 1, Villeurbanne Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques

  • Department of Neurology, Yale University

  • Department NEUROFARBA, University of Florence IRCCS Fondazione Don Carlo Gnocchi

  • Weill Institute of Neurosciences, University of California, San Francisco

  • American University of Beirut Medical Center Harley Street Medical Center

  • Department of Neurology, Royal London Hospital, Barts Health NHS Trust Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London

  • Li Ka Shing Knowledge Institute, St. Michael’s Hospital Division of Neurology, Department of Medicine, St. Michael’s Hospital, University of Toronto

  • Novartis Pharma B.V

Locations

  • Canada

  • France

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Congenital disorder

  • Genetic Disorder

Disease

  • Congenital anomalies

Biomarkers

  • N/A

Drug/Treatment

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • Non Interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved